Previous 10 | Next 10 |
Featured for the 6 th year in a row as the only Indian pharma company in the Bloomberg Gender-Equality Index (GEI) Included in S&P Global’s Sustainability Yearbook for a 3 rd successive year based on its 2022 Corporate Sustainability Assessment (CSA) The company...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Indian markets have been in focus with the recent Hindenburg Research report on the Adani Group. The report alleges that the group has pulled off the “ largest con in corporate history .” The battle continues ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equ...
Dr. Reddy's Laboratories Limited (RDY) Q3 2023 Earnings Conference Call January 25, 2023 08:30 AM ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Amit Agarwal - Head, IR & Director, Finance Conference Call Participants ...
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2023 Q3 earnings call. For further details see: Dr. Reddy's Laboratories Limited 2023 Q3 - Results - Earnings Call Presentation
Dr. Reddy's press release ( NYSE: RDY ): Q3 GAAP EPS of $0.91. Revenue of $818M (+27.2% Y/Y). Gross profit margin at 59.2%. ROCE for the company is 35.8% (annualized). For further details see: Dr. Reddy's GAAP EPS of $0.91, revenue of $818M
Dr. Reddy's Laboratories ( NYSE: RDY ) said it successfully completed the full set of DRL_RI, a potential biosimilar of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) and Biogen's ( BIIB ) blockbuster drug Rituxan (rituximab), for filing in markets including the U.S., Europe...
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE...
Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Phase 1 study conducted by Dr. Reddy’s...
Summary Dr. Reddy's Laboratories is seeing its push into the generics market bear some fruit. However, RDY is also seeing a 23% decline in sales in key segments, due to a drop-off in Sputnik vaccine sales. The decline of COVID related products and the refocusing to new generic...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...